Breakthrough in Cancer Gene Therapy: mRNA Delivery Platforms Show Significant Promise

Strategic Insights -

Researchers at the University of Washington have made significant strides in the field of cancer gene therapy, developing a new mRNA delivery platform that outperforms existing solutions. The platform, called PFHA-PEI-mRNA-HP, utilizes a combination of fluorination and heparinization of low molecular weight polyethylenimine (PEI)-based mRNA complexes to enhance performance. This innovation has shown ultra-high transfection efficiency of 90% across multiple cancer cell types, outperforming the lipid nanoparticle (LNP)-based delivery reagent Lipofectamine 2000.

Key Takeaways:

  • The PFHA-PEI-mRNA-HP platform achieves ultra-high transfection efficiency of 90% across multiple cancer cell types, outperforming Lipofectamine 2000.
  • PFHA-PEI-mRNA-HP demonstrates superior stability compared to Lipofectamine 2000 when stored above 0 degrees C for 15 days.
  • The platform effectively delivers therapeutic IL12 mRNA in vivo and, in combination with anti-PD-L1 therapy, significantly inhibits tumor growth in a triple-negative breast cancer mouse model.
  • PFHA-PEI-mRNA-HP exhibits enhanced physicochemical properties, cellular uptake, endosomal escape capability, and biocompatibility compared to existing platforms.
  • The research suggests that PFHA-PEI-mRNA-HP is a promising candidate for cancer gene therapies, offering a reliable and efficient mRNA delivery platform.
  • The study utilized a polymeric mRNA delivery platform that has structural versatility, durability, and transfection efficiency, making it a promising alternative to LNPs.
  • The research was funded by the Kuni Foundation, National Institutes of Health (NIH), Nanoengineering and Science Institute, and Molecular Engineering and Science Institute, among others.

Statistics:

  • 90% Transfection efficiency of PFHA-PEI-mRNA-HP across multiple cancer cell types.
  • 15 days Storage stability of PFHA-PEI-mRNA-HP above 0 degrees C.
  • Significant inhibition of tumor growth in a triple-negative breast cancer mouse model by PFHA-PEI-mRNA-HP and anti-PD-L1 therapy.

Sources:

  • A Modular Polymer Platform for Efficient Mrna Delivery In Cancer Immunotherapy. Nanoscale Horizons, 2025;10(10):2550-2568. [1]
  • NewsRx. Studies from University of Washington Yield New Information about Cancer Gene Therapy (A Modular Polymer Platform for Efficient Mrna Delivery In Cancer Immunotherapy). Biotech Week. October 15, 2025; p 91. [2]

[1] Royal Soc Chemistry, Thomas Graham House, Science Park, Milton Rd, Cambridge CB4 0WF, Cambs, England

[2] NewsRx LLC